Board meeting on Nov 5, 2026 to consider Q2 and H1 FY27 unaudited results

Revenue growth above 20%EBITDA margin expansionResults View source PDF Explain this filing

SAILIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.3%Reaction day

₹1529.50

prior close

₹1533.90

announcement price

In-mkt

timing

Nifty Smallcap 250market-1.2%+2.5% vs market

Pharmaceuticals peers, median of 173sector-0.8%+2.1% vs sector

On the reaction day the stock moved 2.5 pts more than Nifty Smallcap 250 and 2.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.1

10m

+0.3

15m

+0.8

30m

+0.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.3-1.2+2.5-0.8+2.1

Next day

-1.5-0.8-0.7-1.2-0.3

+2.2+0.6+1.7-0.4+2.7

+1.7+0.7+1.1-0.1+1.9

-1.2-1.7+0.5-3.1+1.9

-2.8-1.3-1.5-3.1+0.3

-4.5+0.2-4.7-3.0-1.5

15d

-5.8-6.9+1.1-7.1+1.2

+1.2-4.5+5.7-4.9+6.1

—————

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Sai Life Sciences has informed the exchanges that its Board of Directors will meet on Thursday, November 5, 2026 to consider and approve the standalone and consolidated unaudited financial results for the second quarter and half year ended September 30, 2026. The trading window for dealing in company securities is closed from October 1 till November 7, 2026 for all designated persons. This is a routine pre-results intimation filed under SEBI Listing Regulations and does not contain any actual financial figures.

Likely market impact

Routine pre-results intimation. Investors should watch for the actual Q2 and H1 FY27 numbers on November 5, 2026.

By the numbersConsolidated · Q2 FY27 vs Q2 FY26

	Q2 FY27	Q2 FY26	Change
Revenue	₹658.6 Cr	₹537.5 Cr	+22.5%
Operating profit	₹127.3 Cr	₹96.73 Cr	+31.6%
Profit after tax	₹98.32 Cr	₹83.84 Cr	+17.3%
EBITDA margin	28.3%	27.1%	+1.2 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.